Millions worldwide grapple with insidious heart conditions, such as Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, which often remain undetected, misdiagnosed, or identified too late for effective intervention. These silent health crises contribute to alarming statistics, with up to 64% of HFpEF cases going unnoticed and cardiac amyloidosis frequently progressing to life-threatening stages before recognition. This critical diagnostic gap underscores an urgent need for advanced solutions in cardiac diagnostics.
Addressing this profound challenge, Ultromics, a pioneering AI healthcare startup originating from Oxford, has successfully secured an impressive $55 million in Series C MedTech funding. This substantial investment is earmarked to significantly advance its groundbreaking EchoGo® platform, a pivotal tool in the fight against these hidden diseases. The funding round was strategically led by prominent investors L&G and Allegis Capital, further bolstered by support from respected healthcare venture capitalists including Oxford Science Enterprises, GV, Blue Venture Fund, and UPMC Enterprises, signaling strong confidence in Ultromics’ vision.
For founder Ross Upton, Ultromics’ mission is deeply personal, stemming from his doctoral studies at Oxford where he witnessed firsthand the devastating consequences of missed heart failure diagnoses. Inspired by the potential of interpreting subtle echocardiography clues more accurately, Upton leveraged advanced machine learning to develop tools capable of detecting what even leading experts might overlook. This drive for earlier intervention embodies the spirit of Oxford innovation in medical technology.
Building upon this foundational vision, Ultromics has meticulously assembled a world-class team dedicated to closing significant diagnostic lacunae in cardiology. Their strategic approach focuses on developing scalable, AI-powered solutions that seamlessly integrate into existing clinical workflows, eliminating the need for additional hardware. The company’s core aim is to democratize access to cutting-edge cardiology tools, extending their reach far beyond specialized academic centers.
Ultromics’ flagship AI diagnostics platform, EchoGo®, exemplifies the transformative power of artificial intelligence in medical imaging analysis. Unlike traditional methods, which often contend with variability and subtle disease indicators, EchoGo® processes routine echocardiograms by leveraging one of the world’s most extensive real-world datasets, comprising over 430,000 scans. This enables the platform to deliver immediate, quantifiable probability scores that are instrumental in identifying the nascent signs of HFpEF and cardiac amyloidosis.
The clinical validation and regulatory achievements of EchoGo® further solidify its position as a game-changer. As the first FDA-approved and fully Medicare-reimbursed AI system specifically for these types of heart failure, EchoGo® effectively bridges the divide between clinical promise and practical application. Rigorous studies have demonstrated its capacity to boost HFpEF detection by more than 70% compared to conventional risk scores. Furthermore, its amyloidosis diagnostic tool, recently honored with a Breakthrough Device designation and validated across 18 leading institutions, consistently outperforms traditional clinical methods in both diagnostic accuracy and disease discrimination, proving the immense potential of heart disease AI.
With this fresh injection of capital, Ultromics is poised for significant nationwide expansion, with a strategic emphasis on key regions such as the US Midwest. Current partnerships with esteemed medical institutions including the University of Chicago Medicine, UPMC, University Hospitals Cleveland, and Northwestern University are already accelerating both clinical adoption and commercial growth. This targeted regional strategy is crucial for widespread impact.
Ross Upton articulates the core problem succinctly: “Hospitals already possess the data; they just lack the tools to unlock its full diagnostic potential.” Ultromics is actively transforming this reality by seamlessly integrating advanced AI healthcare into clinicians’ daily practice. Their mission is to effectively address cardiology’s most persistent diagnostic challenges, thereby profoundly improving patient outcomes and elevating global standards of care, making them a leader among HealthTech startups.
Leave a Reply